Analyst Yaron Werber of TD Cowen reiterated a Buy rating on Legend Biotech, retaining the price target of $62.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yaron Werber has given his Buy rating due to a combination of factors including Legend Biotech’s strong market position and growth potential. The company has demonstrated robust demand for Carvykti, particularly in earlier lines of treatment, and has effectively addressed previous supply constraints with increased manufacturing capacity.
Additionally, Legend Biotech’s strategic focus on expanding community engagement and education about Carvykti’s benefits is expected to drive further demand. The company’s financial outlook is also promising, with a substantial cash runway extending beyond 2026 and anticipated profitability of its joint venture by the end of 2025. These factors collectively underpin Werber’s confidence in Legend Biotech’s continued success and growth trajectory.